Search
Research
Safety and Immunogencity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and ChildrenHighly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role...
Research
Boosting the influenza vaccine schedule in children with cancer: a prospective open-label studyCurrent immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.
News & Events
Pioneering technique opens new window on first week of lifeAn international team of researchers has pioneered a technique which gives unprecedented insight into the dramatic changes occurring in a baby’s body in the first week of life.
News & Events
Australian parents oblivious to true danger of the fluNew research investigating the devastating impact of the 2017 flu season by PAEDS-FluCAN, a national collaboration observing influenza in children, confirmed it was time to take action after thousands of children were hospitalised with the virus last year.
News & Events
Institute celebrates eradication of rubella in AustraliaThe eradication of rubella in Australia is evidence of the vital role vaccinations play in protecting our health, researchers at The Kids Research Institute Australia say.
News & Events
Vaccine surveillance brings safety reassuranceIn 2010, a large number of children experienced febrile convulsions after receiving the FluVax vaccination and many parents began to question its safety.
News & Events
Time running out to prepare for flu seasonPeople are being urged to ensure they've had their vaccination with the 'flu season expected to hit in Western Australia within weeks.
Research
Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational StudyIn mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.
Research
Infant, maternal and demographic predictors of delayed vaccination: A population-based cohort studyReceiving vaccines at or close to their due date (vaccination timeliness) is a now key measure of program performance. However, studies comprehensively examining predictors of delayed infant vaccination are lacking. We aimed to identify predictors of short and longer-term delays in diphtheria-tetanus-pertussis (DTP) vaccination by dose number and ethnicity.
Research
Facilitating knowledge transfer during Australia’s COVID-19 vaccine rollout: an examination of ‘Functional Dialogues’ as an approach to bridge the evidence–policy gapOur interdisciplinary team initiated a project to inform the COVID-19 vaccination programme. We developed a novel research co-creation approach to share emerging findings with government.